The research company Pharmalundensis reported as planned no revenue in the first quarter of 2026. Operating loss increased compared with the same quarter last year. Net sales amounted to zero million kronor (0).Operating profit was -1.5 million kronor (-1.4). Profit before and after tax was -1.6 million kronor (-1.4). Earnings per share amounted to -0.02 kronor (-0.03).Pharmalundensis’ main owner proposes that the annual general meeting on 25 June decide to delist the company’s share from Spotlight to facilitate the financing process. After that, trading in the shares is planned to cease around mid-July.Pharmalundensis’ existing capital is expected to be sufficient for ongoing operations until the end of the year, with limited pace in the projects. However, there is currently no capital available for repayment of the remaining debt from the convertible loan KV1 of 3.2 million kronor. Repayment must therefore be postponed. In addition, there is KV2, which matures in May 2027, of 1.3 million kronor plus interest. It is also not clear whether that convertible loan can be repaid on time.The company plans to carry out a new share issue to existing shareholders in the autumn to keep the company going until a larger international investor has been identified.Pharmalundensis, MkrQ1-2026Q1-2025Net sales00Operating profit-1.5-1.4Profit before tax-1.6-1.4Net profit-1.6-1.4Earnings per share, kronor-0.02-0.03